Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022
- PMID: 36006841
- PMCID: PMC9422959
- DOI: 10.15585/mmwr.mm7134a3
Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022
Abstract
Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).
Beginning the week of March 20–26, 2022, the Omicron BA.2 variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating variant in the United States, accounting for >50% of sequenced isolates.* Data from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed to describe recent COVID-19–associated hospitalization rates among adults aged ≥18 years during the period coinciding with BA.2 predominance (BA.2 period [Omicron BA.2 and BA.2.12.1; March 20–May 31, 2022]). Weekly hospitalization rates (hospitalizations per 100,000 population) among adults aged ≥65 years increased threefold, from 6.9 (week ending April 2, 2022) to 27.6 (week ending May 28, 2022); hospitalization rates in adults aged 18–49 and 50–64 years both increased 1.7-fold during the same time interval. Hospitalization rates among unvaccinated adults were 3.4 times as high as those among vaccinated adults. Among hospitalized nonpregnant patients in this same period, 39.1% had received a primary vaccination series and 1 booster or additional dose; 5.0% had received a primary series and ≥2 boosters or additional doses. All adults should stay up to date† with COVID-19 vaccination, and multiple nonpharmaceutical and medical prevention measures should be used to protect those at high risk for severe COVID-19 illness, irrespective of vaccination status§ (1).
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Andrea George reports grant support from the Council of State and Territorial Epidemiologists (CSTE). Nancy E. Moran reports grant support from CSTE for the population-based Influenza Hospitalization Surveillance Project and COVID-NET activities. Libby Reeg reports institutional support from CSTE. Andy Weigel reports grant support from CSTE for influenza surveillance activities. Evan J. Anderson reports grants for clinical trials from Pfizer, Merck, PaVax, Micron, Sanofi-Pasteur, Janssen, MedImmune, and GlaxoSmithKline; consulting fees from Sanofi-Pasteur, Pfizer, Medscape, Janssen, GlaxoSmithKline, and Moderna; membership on a Kentucky Bioprocessing, Inc., data safety monitoring board and a Sanofi-Pasteur data safety monitoring board, and the endpoint adjudication committee for WCG and ACI Clinical and institutional funding from the National Institutes of Health to conduct clinical trials of COVID-19 vaccines. No other potential conflicts of interest were disclosed.
Figures
Similar articles
-
COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. doi: 10.15585/mmwr.mm7112e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35324880 Free PMC article.
-
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 4;71(5):177-181. doi: 10.15585/mmwr.mm7105e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35113851 Free PMC article.
-
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36264840 Free PMC article.
-
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081. Epidemiol Prev. 2023. PMID: 38314543 Review. English.
-
Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review.Int J Environ Res Public Health. 2023 Jan 25;20(3):2150. doi: 10.3390/ijerph20032150. Int J Environ Res Public Health. 2023. PMID: 36767517 Free PMC article. Review.
Cited by
-
Trends in SARS-CoV-2-related pediatric hospitalizations reported to the Canadian Nosocomial Infection Surveillance Program, March 2020 to December 2022.Antimicrob Steward Healthc Epidemiol. 2024 Oct 17;4(1):e175. doi: 10.1017/ash.2024.427. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 39450098 Free PMC article.
-
Social and Structural Determinants of Health Associated with COVID-19 Vaccine Hesitancy among Older Adults in the United States.Vaccines (Basel). 2024 May 10;12(5):521. doi: 10.3390/vaccines12050521. Vaccines (Basel). 2024. PMID: 38793773 Free PMC article.
-
What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?J Infect Dis. 2024 Aug 16;230(2):382-393. doi: 10.1093/infdis/jiae179. J Infect Dis. 2024. PMID: 38581432
-
COVID-19 vaccines: Immune correlates and clinical outcomes.Hum Vaccin Immunother. 2024 Dec 31;20(1):2324549. doi: 10.1080/21645515.2024.2324549. Epub 2024 Mar 22. Hum Vaccin Immunother. 2024. PMID: 38517241 Free PMC article. Review.
-
A Rapid Environmental Scan of South Florida HIV Organizations' Mpox Messaging During the August 2022 Peak of the U.S. Outbreak.AIDS Behav. 2024 May;28(5):1546-1558. doi: 10.1007/s10461-023-04176-z. Epub 2023 Oct 23. AIDS Behav. 2024. PMID: 37870691 Free PMC article.
References
-
- Delahoy MJ, Whitaker M, O’Halloran A, et al.; COVID-NET Surveillance Team. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19—COVID-NET, 13 States, March 1–August 22, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1347–54. 10.15585/mmwr.mm6938e1 - DOI - PMC - PubMed
-
- Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated—VISION Network, 10 states, December 2021–June 2022. MMWR Morb Mortal Wkly Rep 2022;71:931–9. 10.15585/mmwr.mm7129e1 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
